Roivant Sciences Ltd.
A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.
Bought 4.04M
Granted 8.40M · Sold 16.52M
Sold 26.34M
Sold 15.12M
Sold 13.00M
Granted 100.9K · Sold 25.74M
Granted 26.43M · Sold 4.33M
Granted 23.26M · Bought 3.3K · Sold 4.51M
Granted 100.9K · Sold 17.18M
Sold 22.24M
Granted 16.91M · Sold 3.00M
Granted 14.12M · Sold 13.38M
Sold 13.00M
Granted 567.5K · Sold 408.6K
Granted 1.00M · Sold 971.8K
Granted 135.7K
Granted 141.4K · Sold 13.5K
Granted 124.7K
Granted 52.1K
Granted 114.9K · Sold 70.0K
Granted 64.6K · Sold 41.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. +2 co-filers10% owner · 3 transactions | — | 102.85Mas of Nov 2022 | — | 4.04M | — |
| Ramaswamy Vivek10% owner · 35 transactions | — | 100.92M | 8.40M | — | 16.52M |
| SB Investment Advisers (Uk) LTD +3 co-filers10% owner · 3 transactions | — | 73.03Mas of Sep 2023 | — | — | 26.34M |
| Sumitomo Chemical Co., Ltd. +1 co-filer10% owner · 1 transaction | — | 71.25Mas of Jun 2023 | — | — | 15.12M |
| Halvorsen Ole Andreas +7 co-filers10% owner · 4 transactions | — | 31.41Mas of Jun 2023 | — | — | 13.00M |
| Gold Daniel AllenDirector · 56 transactions | — | 22.66M | 100.9K | — | 25.74M |
| Sukhatme MayukhPresident & CIO, Director · 43 transactions | — | 18.63M | 26.43M | — | 4.33M |
| Gline MatthewCEO, Director · 74 transactions | — | 16.74M | 23.26M | 3.3K | 4.51M |
| Manchester Keith SDirector · 43 transactions | — | 15.44M | 100.9K | — | 17.18M |
| QVT Financial LPDirector by Deputization · 45 transactions | — | 13.69M | — | — | 22.24M |
| Torti FrankPresident and Vant Chair · 12 transactions | — | 13.58M | 16.91M | — | 3.00M |
| Venker EricPresident & Immunovant CEO · 202 transactions | — | 1.60M | 14.12M | — | 13.38M |
| Halvorsen Ole Andreas +7 co-filers10% owner · 4 transactions | — | 641.0Kas of Jun 2023 | — | — | 13.00M |
| Pulik RichardCFO · 55 transactions | — | 271.8K | 567.5K | — | 408.6K |
| Kumar RakhiChief Accounting Officer · 76 transactions | — | 162.3Kas of Feb 2025 | 1.00M | — | 971.8K |
| Oren IlanDirector · 31 transactions | — | 120.2K | 135.7K | — | — |
| Humes JenniferChief Accounting Officer · 5 transactions | — | 109.8K | 141.4K | — | 13.5K |
| Momtazee James CDirector · 31 transactions | — | 109.5K | 124.7K | — | — |
| Lo AndrewDirector · 1 transaction | — | 52.1Kas of Sep 2022 | 52.1K | — | — |
| Fitzgerald MeghanDirector · 12 transactions | — | 43.0K | 114.9K | — | 70.0K |
| Epperly Melissa B,Director · 21 transactions | — | 16.5K | 64.6K | — | 41.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -171.82M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.